• Tiziana Life Sciences announced its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis met both primary endpoints.
• The lower dose significantly reduced neuroinflammation versus placebo; both doses were safe and well tolerated.
• Fatigue improved significantly from baseline with both doses, but disability scores did not change during treatment.
• The higher dose did not significantly reduce neuroinflammation versus placebo.
• Topline results are now available; detailed findings will be presented at a future scientific congress, with FDA discussions planned on further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020700OMX_____CNEWS_EN_GNW9867886_en) on November 02, 2026, and is solely responsible for the information contained therein.